Lucentis gets the green light from regulators

As expected, the FDA on Friday gave its approval to Genentech to market Lucentis for wet, age-related macular degeneration. Genentech says it plans to charge $1,950 a dose for the drug, which will go head-to-head with OSI's Macugen, an early-market entry in the field. OSI acquired Macugen in its acquisition of Eyetech last year. Lucentis has demonstrated clear superiority to a placebo and is expected to rack up blockbuster sales. But Genentech has no plans to compare the effect of Lucentis against its cancer therapy Avastin, which has delivered significant results at a much lower cost for doctors using the therapy off-label. Genentech took 10 years to develop Lucentis.

- here's the AP report on Lucentis

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.